Medicine and Dentistry
Prostate Cancer
100%
Positron Emission Tomography-Computed Tomography
61%
Gallium 68
36%
Prostatectomy
33%
Bone Metastasis
33%
Bone Scintigraphy
30%
Fluorine-18
30%
Magnetic Resonance Imaging
26%
Diagnostic Test Accuracy Study
18%
Radiation Therapy
16%
Diffusion MRI
15%
Biochemical Recurrence
15%
Gleason Score
12%
Treatment Response
10%
Diagnosis
8%
Androgen Deprivation Therapy
7%
Observational Study
7%
Prostate Specific Antigen
7%
Metastatic Carcinoma
7%
Etidronic Acid
6%
Progressive Disease
6%
Extramammary Paget's Disease
6%
Single Photon Emission Computed Tomography-Computed Tomography
6%
Technetium-99
6%
Paget's Disease
6%
Lymph Node
6%
Peyronie's Disease
6%
Surgery
6%
Adverse Event
6%
Cancer Mortality
5%
Keyphrases
18F-sodium Fluoride PET
12%
Clinically Significant Prostate Cancer
6%
Target Delineation
6%
Length of Life
6%
Long-term Toxicity
6%
Prostate Radiotherapy
6%
Imaging Target
6%
Extramammary Paget's Disease
6%
Scrotal Paget's Disease
6%
Preoperative Characteristics
6%
Radical Prostatectomy
6%
Gleason Grade Group
6%
Bone Metastasis
6%
Bone Scintigraphy
6%
Multiparametric MRI (mpMRI)
6%
PROSTVAC
6%
99mTc-methylene Diphosphonate
6%
Penile Metastasis
6%
Biochemical Relapse
6%
Newly Diagnosed
6%
Prostate Zonal Segmentation
6%
Prostate Cancer
6%
Positron Emission Tomography-computed Tomography (PET-CT)
6%
MRI Diffusion
6%
18F-fluoride Positron Emission Tomography
6%
Fluoride
5%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
42%
Gallium 68
18%
Biochemical Recurrence
12%
Castration Resistant Prostate Cancer
9%
Bone Metastasis
9%
Prostate Specific Antigen
8%
Overall Survival
8%
Adverse Event
7%
Observational Study
7%
Fluorine 18
6%
Sodium Fluoride
6%
Placebo
6%
Life Expectancy
6%
Disease
6%
